{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-024789","form_type":"8-K","ticker":"IMCR","cik":"0001671927","company_name":"Immunocore Holdings plc","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.513595+00:00","generated_at":"2026-06-02T10:53:42.180385+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunocore Q1 KIMMTRAK sales $70.3M (+36% YoY); brenetafusp ASCO data; cash $832.8M","bullets":["KIMMTRAK net sales $70.3M, up 36% YoY; US $50.0M, Europe $19.0M, international $1.4M.","Net loss $24.4M ($0.49/sh) vs $19.4M ($0.40/sh) in Q1 2023; R&D $57.5M, SG&A $39.3M.","Cash $832.8M as of Mar 31, 2024, including $390.2M net from Feb 2024 convertible notes; plans to repay $50M loan.","Brenetafusp Phase 1/2 data in late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (May 31).","KIMMTRAK launched in 7 additional countries since Jan 2024; now in 17 countries."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-024789","json":"https://secwatch.observer/filing/0001140361-24-024789.json","markdown":"https://secwatch.observer/filing/0001140361-24-024789.md","text":"https://secwatch.observer/filing/0001140361-24-024789.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124024789/0001140361-24-024789-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124024789/ef20028669_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T10:53:42.180385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"041ef1b37dca8c57560da64e89f45d1e1f20c091","claim":"Immunocore Holdings plc reported the first quarter ended March 31, 2024 results: revenue Total net product revenue ... was $70.3 million in the first quarter of 2024, net income Net loss for the first quarter of 2024 was $24.4 million, EPS The first quarter basic and diluted loss per share was $0.49.","evidence_excerpt":"On May 8, 2024, Immunocore Holdings plc (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024, as well as other recent corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124024789/0001140361-24-024789-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"Total net product revenue ... was $70.3 million in the first quarter of 2024"},{"label":"Net income","value":"Net loss for the first quarter of 2024 was $24.4 million"},{"label":"EPS","value":"The first quarter basic and diluted loss per share was $0.49"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}